Meta-analysis of the feasibility of sentinel lymph node biopsy in breast cancer patients with axillary lymph nodes turned to negative after neoadjuvant chemotherapy
10.3760/cma.j.cn115396-20220726-00245
- VernacularTitle:新辅助化疗后腋窝淋巴结转阴的乳腺癌患者进行前哨淋巴结活检可行性的Meta分析
- Author:
Yaqian LIU
1
;
Li FENG
;
Feiyue GUO
;
Yelin HE
;
Yiran ZHAO
;
Jing ZHANG
Author Information
1. 河北北方学院研究生学院，张家口 075000
- Keywords:
Breast neoplasms;
Sentinel lymph node biopsy;
Neoadjuvant chemotherapy;
Meta-analysis
- From:
International Journal of Surgery
2023;50(2):86-93
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the feasibility of sentinel lymph node biopsy in breast cancer patients with positive axillary lymph nodes turned to clinical negative after neoadjuvant chemotherapy.Methods:Full-text journal databases such as PubMed, Cochrane Library, Embase, Wanfang, VIP, and CNKI were searched to include research literature on sentinel lymph node biopsy in breast cancer patients who had axillary lymph nodes turned negative after neoadjuvant chemotherapy. The retrieval time was self-established to November 2020. Meta-analysis was performed on the literature that met the inclusion criteria. Heterogeneity among studies was analyzed by I2 test. If I2<30%, the heterogeneity among studies was considered to be small. If the value of I2 was between 30% and 70%, it was considered that there was a certain heterogeneity among the studies. If I2> 70%, it was considered that there was great heterogeneity among the studies. Small heterogeneity was analyzed by fixed effects model, otherwise, random effects model was used. Publication bias was evaluated by funnel plot and Egger′s test. Results:Finally, 14 literatures were included, including 4 Chinese literatures and 10 English literatures. The results of Meta-analysis showed that the sentinel lymph node detection rate was 90.7% and the false negative rate was 12.2%.Conclusions:In breast cancer patients with axillary lymph node turning negative, the detection rate of sentinel lymph node biopsy can meet the acceptable clinical standard for sentinel lymph node biopsy, but the false negative rate is still higher than the clinically acceptable standard. It is necessary to screen suitable patients and apply new techniques to reduce the false negative rate of sentinel lymph node biopsy.
